Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy.
This paper sought to determine if the fixed-dose combination of trandolapril and verapamil is effective in the treatment of hypertensive obese patients resistant to monotherapy. Thirty-six hypertensive obese patients uncontrolled by monotherapy were given the combination of trandolapril-verapamil (2/180 mg) for 12 weeks. Before and after taking the drug, they self-measured their blood pressure. Patients experienced a significant reduction of blood pressure (from 178 +/- 18/100 +/- 12 mm Hg to 135 +/- 14/76 +/- 7 mm Hg, p < 0.001). Eighty percent of patients reached therapeutic goals; one patient suffered from headaches and one had constipation. it was determined that the combination of trandolapril-verapamil is effective and safe for the management of hypertension in obese patients uncontrolled by monotherapy.
Rubio-Guerra
Alberto Francisco
AF
Hypertension Clinic, Hospital General de Ticomán SS DF, Mexico City, México. clinhta@hotmail.com
Lozano-Nuevo
José Juan
JJ
Vargas-Ayala
Germán
G
Rodríguez-López
Leticia
L
Ramos-Brizuela
Luz María
LM
Escalante-Acosta
Bruno Alfonso
BA
D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008800:Mexico; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000503:physiopathology; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D004338:Drug Combinations; D007211:Indoles; D014665:Vasodilator Agents; C052035:trandolapril; D014700:Verapamil